Mizuho raised the firm’s price target on Immuneering (IMRX) to $10 from $8 and keeps an Outperform rating on the shares. The company announced positive updated Phase 2a data for lead asset IMM-1-104 in first-line pancreatic cancer in combination with modified Gemcitabine, a standard-of-care treatment, the analyst tells investors in a research note. The firm came away “very impressed” by this first look at the overall survival and progression-free survival data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly
- Immuneering Announces Promising Phase 2a Trial Results
- Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer
- Immuneering Elects New Directors at Annual Meeting